Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice

Clothilde Roche, Dominique Guerrot, Najah Harouki, Thomas Duflot, Marie Besnier, Isabelle Rémy-Jouet, Sylvanie Renet, Anaïs Dumesnil, Annie Lejeune, Christophe Morisseau, Vincent Richard, Jeremy Bellien

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

This study addressed the hypothesis that inhibition of the EETs degrading enzyme soluble epoxide hydrolase affords renal protection in the early stage of diabetic nephropathy. The renal effects of the sEH inhibitor t-AUCB (10 mg/l in drinking water) were compared to those of the sulfonylurea glibenclamide (80 mg/l), both administered for 8 weeks in FVB mice subjected to a high-fat diet (HFD, 60% fat) for 16 weeks. Mice on control chow diet (10% fat) and non-treated HFD mice served as controls. Compared with non-treated HFD mice, HFD mice treated with t-AUCB had a decreased EET degradation, as shown by their higher plasma EETs-to-DHETs ratio, and an increased EET production, as shown by the increase in EETs + DHETs levels, which was associated with induction of CYP450 epoxygenase expression. Both agents similarly reduced fasting glycemia but only t-AUCB prevented the increase in the urinary albumine-to-creatinine ratio in HFD mice. Histopathological analysis showed that t-AUCB reduced renal inflammation, which was associated with an increased mRNA expression of the NFκB inhibitor Iκ≡ and related decrease in MCP-1, COX2 and VCAM-1 expressions. Finally, there was a marginally significant increase in reactive oxygen species production in HFD mice, together with an enhanced NOX2 expression. Both agents did not modify these parameters but t-AUCB increased the expression of the antioxidant enzyme superoxide dismutase 1. These results demonstrate that, independently from its glucose-lowering effect, sEH inhibition prevents microalbuminuria and renal inflammation in overweight hyperglycemic mice, suggesting that this pharmacological strategy could be useful in the management of diabetic nephropathy.

Original languageEnglish (US)
Article number6124
Pages (from-to)148-154
Number of pages7
JournalProstaglandins and Other Lipid Mediators
Volume120
DOIs
StatePublished - Jul 1 2015

Fingerprint

Epoxide Hydrolases
Obese Mice
Kidney
Fats
Nutrition
Diabetic Nephropathies
Vascular Cell Adhesion Molecule-1
Glyburide
Enzymes
Inflammation
Drinking Water
Superoxide Dismutase
Reactive Oxygen Species
Creatinine
High Fat Diet
Antioxidants
Inhibition (Psychology)
4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid
Plasmas
Glucose

Keywords

  • Diabetes
  • Diabetic nephropathy
  • Renal inflammation
  • Soluble epoxide hydrolase

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Pharmacology
  • Cell Biology

Cite this

Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice. / Roche, Clothilde; Guerrot, Dominique; Harouki, Najah; Duflot, Thomas; Besnier, Marie; Rémy-Jouet, Isabelle; Renet, Sylvanie; Dumesnil, Anaïs; Lejeune, Annie; Morisseau, Christophe; Richard, Vincent; Bellien, Jeremy.

In: Prostaglandins and Other Lipid Mediators, Vol. 120, 6124, 01.07.2015, p. 148-154.

Research output: Contribution to journalArticle

Roche, C, Guerrot, D, Harouki, N, Duflot, T, Besnier, M, Rémy-Jouet, I, Renet, S, Dumesnil, A, Lejeune, A, Morisseau, C, Richard, V & Bellien, J 2015, 'Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice', Prostaglandins and Other Lipid Mediators, vol. 120, 6124, pp. 148-154. https://doi.org/10.1016/j.prostaglandins.2015.04.011
Roche, Clothilde ; Guerrot, Dominique ; Harouki, Najah ; Duflot, Thomas ; Besnier, Marie ; Rémy-Jouet, Isabelle ; Renet, Sylvanie ; Dumesnil, Anaïs ; Lejeune, Annie ; Morisseau, Christophe ; Richard, Vincent ; Bellien, Jeremy. / Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice. In: Prostaglandins and Other Lipid Mediators. 2015 ; Vol. 120. pp. 148-154.
@article{5d90958716584d7d9e6adb2dbb3ab0bb,
title = "Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice",
abstract = "This study addressed the hypothesis that inhibition of the EETs degrading enzyme soluble epoxide hydrolase affords renal protection in the early stage of diabetic nephropathy. The renal effects of the sEH inhibitor t-AUCB (10 mg/l in drinking water) were compared to those of the sulfonylurea glibenclamide (80 mg/l), both administered for 8 weeks in FVB mice subjected to a high-fat diet (HFD, 60{\%} fat) for 16 weeks. Mice on control chow diet (10{\%} fat) and non-treated HFD mice served as controls. Compared with non-treated HFD mice, HFD mice treated with t-AUCB had a decreased EET degradation, as shown by their higher plasma EETs-to-DHETs ratio, and an increased EET production, as shown by the increase in EETs + DHETs levels, which was associated with induction of CYP450 epoxygenase expression. Both agents similarly reduced fasting glycemia but only t-AUCB prevented the increase in the urinary albumine-to-creatinine ratio in HFD mice. Histopathological analysis showed that t-AUCB reduced renal inflammation, which was associated with an increased mRNA expression of the NFκB inhibitor Iκ≡ and related decrease in MCP-1, COX2 and VCAM-1 expressions. Finally, there was a marginally significant increase in reactive oxygen species production in HFD mice, together with an enhanced NOX2 expression. Both agents did not modify these parameters but t-AUCB increased the expression of the antioxidant enzyme superoxide dismutase 1. These results demonstrate that, independently from its glucose-lowering effect, sEH inhibition prevents microalbuminuria and renal inflammation in overweight hyperglycemic mice, suggesting that this pharmacological strategy could be useful in the management of diabetic nephropathy.",
keywords = "Diabetes, Diabetic nephropathy, Renal inflammation, Soluble epoxide hydrolase",
author = "Clothilde Roche and Dominique Guerrot and Najah Harouki and Thomas Duflot and Marie Besnier and Isabelle R{\'e}my-Jouet and Sylvanie Renet and Ana{\"i}s Dumesnil and Annie Lejeune and Christophe Morisseau and Vincent Richard and Jeremy Bellien",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.prostaglandins.2015.04.011",
language = "English (US)",
volume = "120",
pages = "148--154",
journal = "Prostaglandins and Other Lipid Mediators",
issn = "1098-8823",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice

AU - Roche, Clothilde

AU - Guerrot, Dominique

AU - Harouki, Najah

AU - Duflot, Thomas

AU - Besnier, Marie

AU - Rémy-Jouet, Isabelle

AU - Renet, Sylvanie

AU - Dumesnil, Anaïs

AU - Lejeune, Annie

AU - Morisseau, Christophe

AU - Richard, Vincent

AU - Bellien, Jeremy

PY - 2015/7/1

Y1 - 2015/7/1

N2 - This study addressed the hypothesis that inhibition of the EETs degrading enzyme soluble epoxide hydrolase affords renal protection in the early stage of diabetic nephropathy. The renal effects of the sEH inhibitor t-AUCB (10 mg/l in drinking water) were compared to those of the sulfonylurea glibenclamide (80 mg/l), both administered for 8 weeks in FVB mice subjected to a high-fat diet (HFD, 60% fat) for 16 weeks. Mice on control chow diet (10% fat) and non-treated HFD mice served as controls. Compared with non-treated HFD mice, HFD mice treated with t-AUCB had a decreased EET degradation, as shown by their higher plasma EETs-to-DHETs ratio, and an increased EET production, as shown by the increase in EETs + DHETs levels, which was associated with induction of CYP450 epoxygenase expression. Both agents similarly reduced fasting glycemia but only t-AUCB prevented the increase in the urinary albumine-to-creatinine ratio in HFD mice. Histopathological analysis showed that t-AUCB reduced renal inflammation, which was associated with an increased mRNA expression of the NFκB inhibitor Iκ≡ and related decrease in MCP-1, COX2 and VCAM-1 expressions. Finally, there was a marginally significant increase in reactive oxygen species production in HFD mice, together with an enhanced NOX2 expression. Both agents did not modify these parameters but t-AUCB increased the expression of the antioxidant enzyme superoxide dismutase 1. These results demonstrate that, independently from its glucose-lowering effect, sEH inhibition prevents microalbuminuria and renal inflammation in overweight hyperglycemic mice, suggesting that this pharmacological strategy could be useful in the management of diabetic nephropathy.

AB - This study addressed the hypothesis that inhibition of the EETs degrading enzyme soluble epoxide hydrolase affords renal protection in the early stage of diabetic nephropathy. The renal effects of the sEH inhibitor t-AUCB (10 mg/l in drinking water) were compared to those of the sulfonylurea glibenclamide (80 mg/l), both administered for 8 weeks in FVB mice subjected to a high-fat diet (HFD, 60% fat) for 16 weeks. Mice on control chow diet (10% fat) and non-treated HFD mice served as controls. Compared with non-treated HFD mice, HFD mice treated with t-AUCB had a decreased EET degradation, as shown by their higher plasma EETs-to-DHETs ratio, and an increased EET production, as shown by the increase in EETs + DHETs levels, which was associated with induction of CYP450 epoxygenase expression. Both agents similarly reduced fasting glycemia but only t-AUCB prevented the increase in the urinary albumine-to-creatinine ratio in HFD mice. Histopathological analysis showed that t-AUCB reduced renal inflammation, which was associated with an increased mRNA expression of the NFκB inhibitor Iκ≡ and related decrease in MCP-1, COX2 and VCAM-1 expressions. Finally, there was a marginally significant increase in reactive oxygen species production in HFD mice, together with an enhanced NOX2 expression. Both agents did not modify these parameters but t-AUCB increased the expression of the antioxidant enzyme superoxide dismutase 1. These results demonstrate that, independently from its glucose-lowering effect, sEH inhibition prevents microalbuminuria and renal inflammation in overweight hyperglycemic mice, suggesting that this pharmacological strategy could be useful in the management of diabetic nephropathy.

KW - Diabetes

KW - Diabetic nephropathy

KW - Renal inflammation

KW - Soluble epoxide hydrolase

UR - http://www.scopus.com/inward/record.url?scp=84941804237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941804237&partnerID=8YFLogxK

U2 - 10.1016/j.prostaglandins.2015.04.011

DO - 10.1016/j.prostaglandins.2015.04.011

M3 - Article

C2 - 26022136

AN - SCOPUS:84941804237

VL - 120

SP - 148

EP - 154

JO - Prostaglandins and Other Lipid Mediators

JF - Prostaglandins and Other Lipid Mediators

SN - 1098-8823

M1 - 6124

ER -